SCHEMBL8663352

SCHEMBL8663352

CNC(CCCCNC(=N)N)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 9/20 0.43
ALOX15 P16050 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
KMT2A Q03164 1/20 0.39
NOD1 Q9Y239 1/20 0.36
SIRT6 Q8N6T7 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
TLR2 O60603 1/20 0.35
SIRT5 Q9NXA8 1/20 0.35
NPY4R P50391 3/20 0.35
NPY1R P25929 2/20 0.35
NPY2R P49146 2/20 0.35
NPY5R Q15761 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL350358 1.00 FOLH1 (0.43) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
SCHEMBL29888878 1.00 FOLH1 (0.43) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
Acetic Acid SCHEMBL4407896 0.97 FOLH1 (0.44) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
SCHEMBL93473 0.95 FOLH1 (0.38) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
SCHEMBL17769024 0.95 FOLH1 (0.38) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
SCHEMBL93472 0.95 FOLH1 (0.38) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
SCHEMBL162756 0.95 FOLH1 (0.38) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
Hydrochloric Acid SCHEMBL1578565 0.93 FOLH1 (0.37) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
Hydrochloric Acid SCHEMBL7367067 0.93 FOLH1 (0.37) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
Hydrochloric Acid SCHEMBL974818 0.93 FOLH1 (0.37) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023219952-A1 MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2023-11-16 WO claimed
US-12521455-B2 Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof RADIONETICS ONCOLOGY, INC. (US) 2026-01-13 US disclosed
US-20230405157-A1 MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2023-12-21 US disclosed
WO-2023219952-A1 MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2023-11-16 WO disclosed
EP-0649303-B1 SUBSTITUTED ARGININES AND SUBSTITUTED HOMOARGININES AND USE THEREOF CORNELL RES FOUNDATION INC (US) 1998-11-25 EP disclosed
EP-0649303-A4 SUBSTITUTED ARGININES AND SUBSTITUTED HOMOARGININES AND USE THEREOF. CORNELL RES FOUNDATION INC (US) 1995-07-05 EP disclosed
EP-0649303-A1 SUBSTITUTED ARGININES AND SUBSTITUTED HOMOARGININES AND USE THEREOF CORNELL RESEARCH FOUNDATION, INC. (US) 1995-04-26 EP disclosed
WO-1993024126-A1 SUBSTITUTED ARGININES AND SUBSTITUTED HOMOARGININES AND USE THEREOF CORNELL RESEARCH FOUNDATION, INC. (US) 1993-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230405157-A1 MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF MC3R, MC1R, MC4R FOLH1 212/4885ALOX15 4193/4885SMN1; SMN2 4564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.